Norroy Bioscience Initiates Crucial Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Driven Radioligand Therapy for mCRPC

On September 2, 2026, Approval has been given in China to Norroy Bioscience for initiating an important Phase III trial of 177Lu-NYM032, a promising targeted radioactive therapy for men with PSMA-positive metastatic castration resistant prostate cancer who no longer respond to hormone treatment. This approval follows positive results from the Phase I/II studies, in which the therapy was found to be able to battle tumors and to be safe to use. The trial will examine the safety and effectiveness of the therapy at a number of medical hubs in China for radioligand therapy.

These agents are based on the same starting material, which may help in concerning patient selection for treatment using FDA clearance. The company is developing 68Ga-NYM032, a diagnostic agent designed to work well with the treatment as part of an integrated diagnosis and therapy strategy. The progression to Phase III not only accelerates Norroy's position in the field of targeted radioactive medicines but also reflects the increasing progress in personalized medicine for advanced prostate cancer.

Impact on the Radiopharmaceutical Industry

The global radiopharmaceuticals market size is accounted at USD 7.51 billion in 2025 and predicted to increase from USD 8.28 billion in 2026 to approximately USD 15.21 billion by 2035, representing a CAGR of 7.31% from 2026 to 2035.

According to Precedence Research, the move into Phase III could boost the expansion in the area of radiopharmaceutical sector. At present, PSMA-targeted treatments are being highlighted because they allow radioactive materials to be delivered directly to prostate cancer cells without damaging healthy tissue. The development of a complementary diagnostic agent highlights the increasing significance of theranostic platforms, as imaging is used to select patients prior to giving them treatment.

Norroy's progress currently offers one stronger challenger in a very competitive late-stage pipeline. If the programme is successful, it may result in additional investment in radioligand research, manufacturing capabilities, isotope creation, and the creation of specialised treatment infrastructure in developing and more established frameworks.

Impact on the Oncology Industry

The global oncology market size was calculated at USD 250.88 billion in 2025 and is predicted to increase from USD 279.73 billion in 2026 to approximately USD 732.45 billion by 2035, expanding at a CAGR of 11.31% from 2026 to 2035.

According to Precedence Research, the Phase III trial for Norroy may offer new hope to patients with advanced prostate cancer, especially those whose cancer has not responded to previous treatments. The oncology sector's future of 177Lu-NYM032 will depend on its clinical effectiveness, availability, safety, and the ability to scale up manufacturing. This accomplishment is a breakthrough for pharmaceutical firms since mCRPC is a difficult condition with considerable unmet medical needs.

The programme is likely to increase the competitive edge among the companies working on PSMA-targeted therapies. In the end, if the radioligand therapy proves successful, it could widen the use of targeted radiation and thus act as a complement to current hormonal, chemical, and other systemic therapies.

Impact on the Nuclear Medicine Industry

The global nuclear medicine market size is valued at USD 13.21 billion in 2025 and is predicted to increase from USD 14.72 billion in 2026 to approximately USD 38.39 billion by 2035, expanding at a CAGR of 11.26% from 2026 to 2035.

According to Precedence Research, this trial has the potential to transform the field of nuclear medicine by demonstrating the commercial viability of united diagnostic and therapeutic radiopharmaceuticals. In the nuclear medicine industry, the use of 68Ga-NYM032 and 177Lu-NYM032, which are based on the same molecular structure, might simplify the procedure from identifying the patient to delivering targeted treatment.

When a greater number of radioligand therapies reach late-stage development, healthcare systems will probably have to make investments in specialised facilities, skilled personnel, and dependable isotope supply chains. This kind of innovation could increase the demand for advanced imaging techniques, expertise in radiopharmacy, and a reliable infrastructure for managing isotopes.

Expert Opinion

From an expert point of view, the early indications of antitumor activity and tolerability are promising it is a controlled trial that will determine whether these translate into actual clinical benefits. The expert said that the competitive edge in the area of PSMA-targeted prostate cancer is becoming more intense to distinguish this therapy from the others.

If, in clinical trials and at commercial scale, the Phase III results are positive, Norroy could establish itself as a leading player in radiopharmaceutical oncology, biotechnology and pharmaceutical sector and thus contribute to wider acceptance of theranostic methods. Additionally, the success of the programme will depend on the quality of its safety, efficacy, and patient-selection data.